Loading organizations...
Loading organizations...
Elypta: Biotech company developing metabolism-based liquid biopsy diagnostics for multi-cancer early detection and kidney cancer recurrence.
Based in Stockholm, Sweden, Elypta is a biotechnology company developing a metabolism-based liquid biopsy platform that uses blood and urine tests for multi-cancer early detection and kidney cancer recurrence monitoring. The company's diagnostic technology profiles glycosaminoglycans as biomarkers of tumor metabolism, enabling the detection of more than twelve different cancer types in asymptomatic adults. To support its clinical development and commercialization efforts, the enterprise has raised $30 million in total funding over eight years, which includes a $21 million Series A round. Elypta is backed by venture capital investors such as Bonnier Ventures, Chalmers Ventures, Industrifonden, and Norrsken VC, and recently won a $1 million grand prize from the Roddenberry Foundation. The ISO 13485-certified organization, which has published over ten peer-reviewed scientific research papers, was founded in 2017 by Francesco Gatto and Jens Nielsen.
Elypta has raised $27.8M across 2 funding rounds.
Elypta has raised $27.8M in total across 2 funding rounds.
Elypta has raised $27.8M in total across 2 funding rounds.
Elypta's investors include Sofia Hasselberg, Chalmers Ventures, Hillclimber, Jonas Jendi, Locust Walk, Nina Capital, Norrsken VC, Wallenberg Investments, Sciety.
Elypta has raised $27.8M across 2 funding rounds. Most recently, it raised $21.0M Series A in June 2022.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Jun 20, 2022 | $21.0M Series A | Sofia Hasselberg | Chalmers Ventures, Hillclimber, Jonas Jendi, Locust Walk, Nina Capital, Norrsken VC, Wallenberg Investments |
| Jan 23, 2020 | $6.8M Seed | Jonas Jendi, Sciety | Chalmers Ventures, Nina Capital, Norrsken VC |